1-(1- (2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino) - 1H-Pyrazolo [4,3-D] Pyrimidin-5-YL) Piperidine-4-Carboxylic acid and salts thereof

Abstract

The present invention comprises 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts. The invention further comprises pharmaceutical compositions, methods of treatment, and synthetic methods relating to 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts.

1 . A compound, and pharmaceutically acceptable salts of the compound, having the structure: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The compound of  claim 1  that is a free acid. 
     
     
         3 . The pharmaceutically acceptable salts of the compound of  claim 1 . 
     
     
         4 . A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt of the compound, having the structure: 
       
         
           
           
               
               
           
         
       
       a pharmaceutically-acceptable carrier. 
     
     
         5 . The pharmaceutical composition of  claim 4  comprising a free acid of the compound. 
     
     
         6 . The pharmaceutical composition of  claim 4  comprising a pharmaceutically acceptable salt of the compound. 
     
     
         7 . The pharmaceutical composition of  claim 4  further comprising an angiotensin converting enzyme inhibitor. 
     
     
         8 . The pharmaceutical composition of  claim 4  further comprising an angiotensin II receptor antagonist. 
     
     
         9 . A method of treating a condition in a subject, the method comprising administering to the subject a therapeutically-effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the structure: 
       
         
           
           
               
               
           
         
       
       wherein the condition is selected from the group consisting of a cardiovascular condition, a metabolic condition, a central nervous system condition, a pulmonary condition, sexual dysfunction, pain and renal dysfunction. 
     
     
         10 . The method of  claim 9  wherein the condition is a cardiovascular condition. 
     
     
         11 . The method of  claim 10  wherein the cardiovascular condition is hypertension. 
     
     
         12 . The method of  claim 10  wherein the cardiovascular condition is heart failure. 
     
     
         13 . The method of  claim 10  wherein the cardiovascular condition is angina. 
     
     
         14 . The method of  claim 9  further comprising administering a therapeutically-effective amount of an angiotensin converting enzyme inhibitor to the subject. 
     
     
         15 . The method of  claim 9  further comprising administering a therapeutically-effective amount of an angiotensin II receptor antagonist to the subject. 
     
     
         16 . Use of a compound, or a pharmaceutically acceptable salt thereof, having the structure: 
       
         
           
           
               
               
           
         
       
       in the manufacture of a medicament for the treatment of a condition selected from the group consisting of cardiovascular conditions, metabolic conditions, central nervous system conditions, pulmonary conditions, sexual dysfunction, pain and renal dysfunction. 
     
     
         17 . The use of  claim 16  wherein the condition is a cardiovascular condition. 
     
     
         18 . The use of  claim 17  wherein the cardiovascular condition is hypertension. 
     
     
         19 . The use of  claim 17  wherein the cardiovascular condition is heart failure. 
     
     
         20 . The use of  claim 18  wherein the cardiovascular condition is angina. 
     
     
         21 . A method of preparing a first compound having the structure: 
       
         
           
           
               
               
           
         
         The method comprising contacting a second compound having the structure: 
       
       
         
           
           
               
               
           
         
         with isonipecotic acid to provide the first compound.